Impact of Alpha-Fetoprotein Surge in Testicular Cancer Treatment
Author Information
Author(s): R de Wit, L Collette, R Sylvester, PHM de Mulder, DT Sleijfer, WW ten Bokkel Huinink, SB Kaye, AT van Oosterom, E Boven, G Stoter
Primary Institution: Rotterdam Cancer Institute and University Hospital
Hypothesis
Does a surge in serum alpha-fetoprotein after chemotherapy initiation indicate worse prognosis in non-seminomatous testicular cancer?
Conclusion
An alpha-fetoprotein surge after chemotherapy initiation is a strong adverse prognostic factor for disease progression.
Supporting Evidence
- Of 352 patients with elevated AFP, 101 (29%) had a surge.
- An AFP surge was retained in the final model for progression.
- HCG surge showed no prognostic significance for progression or survival.
Takeaway
If a patient with testicular cancer has a spike in a certain blood marker after starting treatment, it might mean their cancer is not responding well.
Methodology
The study analyzed serum alpha-fetoprotein and human chorionic gonadotrophin levels in patients treated with cisplatin combination chemotherapy, assessing the prognostic significance of marker surges.
Limitations
The study's findings on survival were not statistically significant due to low event numbers.
Participant Demographics
Patients treated between 1983 and 1991 for non-seminomatous testicular cancer.
Statistical Information
P-Value
0.005
Confidence Interval
1.28-4.04
Statistical Significance
p=0.005
Want to read the original?
Access the complete publication on the publisher's website